• Explore /
  • Poster
  • / Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway.

Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway.

Abstract Poster

Authors

null

John D. Hainsworth

Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN

John D. Hainsworth , Ron Bose , Christopher Sweeney , Funda Meric-Bernstam , Herbert Hurwitz , Charles Swanton , Howard A. Burris III, Razelle Kurzrock , Bongin Yoo , Mary Stanley Beattie , Rajesh D. Patel , Katja Schulze , David R. Spigel , Ravindra Gupta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02091141

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9073)

DOI

10.1200/JCO.2017.35.15_suppl.9073

Abstract #

9073

Poster Bd #

399

Abstract Disclosures

Similar Posters

First Author: Razelle Kurzrock

First Author: Lee A Albacker

First Author: Herbert Hurwitz

First Author: Howard A. Burris III